UT-MYHERITAGE
13.10.2020 07:21:10 CEST | Business Wire | Pressemeddelelse
MyHeritage , den førende globale tjeneste til at opdage din fortid og tage kontrol over din fremtid, annoncerede i dag offentliggørelsen af en omfattende samling af norske kirkebogsoptegnelser. MyHeritage har digitaliseret denne samling i samarbejde med Arkivverket, det norske rigsarkiv. Denne tilføjelse fordobler antallet af norske historiske optegnelser på MyHeritage og bringer den samlede antal norske historiske optegnelser i MyHeritages database op på 12,6 milliarder.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20201012005885/da/
Samlingen Norge Kirkebøger (1815-1938) består af 42,2 millioner fødsels-, dåbs-, vielses-, døds- og begravelsesoptegnelser, som er dokumenteret af Norges evangelisk-lutherske kirke, som udførte arbejdet med at dokumentere vitale optegnelser på regeringens vegne. Samlingen indeholder et indeks over transskriberede optegnelser og digitale billeder af de originale kirkedokumenter. Billederne har været tilgængelige gennem Norges rigsarkiv i adskillige år, men har ikke været søgbare efter navn. Dette er første gang, at kirkebøger fra Norge er blevet indekseret og gjort tilgængelige online.
Optegnelserne i denne samling dateres tilbage til 1815 og dækker en vigtig periode i Norges historie, der begynder kun et år efter dets løsrivelse fra Danmark. Denne vigtige samling hjælper med at dække de store huller i norske folketællinger fra 1801 til 1865. Fem folketællinger blev indsamlet i Norge i disse år, men de registrerede ikke navne på enkeltpersoner, hvilket gjorde kirkebøgerne til den hovedsagelige kilde til slægtsdata i den periode. På grund af norsk privatlivslov strækker fødsels- og dåbsoptegnelserne, der er inkluderet i denne samling, til og med 1919, vielsesoptegnelserne strækker sig til og med 1937, og døds- og begravelsesoptegnelserne strækker sig til og med 1938.
Med udgivelsen af denne samling har MyHeritage nu 80 millioner historiske optegnelser fra Norge. Som markedsleder inden for skandinavisk slægtsforskning, tilbyder MyHeritage også 157 millioner historiske optegnelser fra Sverige og 107 millioner optegnelser fra Danmark. MyHeritage er det eneste store slægtsforskningsfirma, der leverer sine tjenester og fuld kundesupport på alle tre skandinaviske sprog såvel som på finsk, og tilbyder den bedste mulighed for nye slægtshistoriske opdagelser for alle med skandinavisk oprindelse. MyHeritages popularitet i Norge er så høj, at en ud af fem nordmænd er en registreret bruger af MyHeritage.
”Norske kirkebogsoptegnelser er en vigtig ressource til at udforske norsk arv og forbedrer de norske historiske optegnelser, der er tilgængelige på MyHeritage, betydeligt,” sagde Russ Wilding, Chief Content Officer for MyHeritage. "Ud over det norske folk, vil millioner af mennesker med norsk herkomst, som bor udenfor Norge, få glæde af denne samling og få nye gennembrud i deres slægtshistoriske forskning."
Norges kirkebøger er tilgængelig på MyHeritages søgemaskine til historiske optegnelser. Det er gratis at søge i samlingen. Der kræves et abonnement for at se de komplette optegnelser og for at få adgang til Record Matches.
Søg i den nye Norge Kirkebøger .
Om MyHeritage
MyHeritage er den førende globale platform til at opdage og udforske slægtshistorie. Med milliarder af historiske optegnelser og slægttræsprofiler og med sofistikerede matching-teknologier på tværs af alle dens aktiver, giver MyHeritage brugere mulighed for at opdage deres fortid og tage kontrol over deres fremtid. Siden 2020 er MyHeritage stedet for verdens bedste teknologier til forbedring og farvelægning af historiske fotos. MyHeritage er den mest populære tjeneste for slægtshistorie i Europa. www.myheritage.dk
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20201012005885/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum